806
Participants
Start Date
January 13, 2022
Primary Completion Date
December 13, 2022
Study Completion Date
December 13, 2022
Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B
42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B
42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B
42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B
40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B
Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A
42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
High Point Clinical Trials Center, High Point
M3 Wake Research, Inc., Raleigh
Monroe Biomedical Research, Monroe
Coastal Carolina Research Center, North Charleston
Infinite Clinical Trials, Morrow
Bright Research Center, Miami
AMR Knoxville, Knoxville
AMR Lexington, Lexington
Centricity Research, Columbus
AMR Kansas City, Kansas City
QPS Bio-Kinetic, Springfield
Woodland International Research Group, Little Rock
Pillar Clinical Research, LLC, Bentonville
Woodland Research Northwest, Rogers
Pillar Clinical Research, Richardson
InSite Clinical Research, LLC., DeSoto
Clinical Trials of Texas, San Antonio
Endeavor Clinical Trials, San Antonio
Collaborators (1)
Celerion
INDUSTRY
British American Tobacco (Investments) Limited
INDUSTRY